Candidate drug EDP-305 reduced fibrosis progression and improved non-alcoholic fatty liver disease (NAFLD) and primary biliary cholangitis (PBC) disease settings in several preclinical animal models, says…
Cholangitis
Recent Posts
- AI model based on imaging, blood tests may help diagnose biliary atresia
- New hepatitis D drug brelovitug marks milestones in late-stage trials
- Study finds ethnic disparities in common liver disease treatment
- Living with MASH reminds me to avoid making assumptions
- Particles in grilled meats may trigger liver disease, mouse study finds